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OA is the most common chronic disease affecting the 
joints with about a 45 % lifetime risk of developing OA 
of the knee [1, 2]. It can affect any joint, but it occurs 
most often in knees, hips, spine, or hands. Symptoms 
include pain and stiffness, bony enlargement, crepitus 
with movement and decreased function of the joint.  OA 
pathogenesis is complex and includes multiple risk 
factors that are still incompletely known, but old age is 
a critical contributor [3, 4]. The relationship between 
old age and OA is not  fully  understood.  Classically,  it  
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was suspected that the association was related to the 
“wear and tear” of articular cartilage by continuous 
mechanical stress. Today, we know that this model of 
OA is insufficient because OA involves an active 
response to injury comprising remodeling of articular 
cartilage and neighboring bone, in addition of synovial 
inflammation and damage to ligaments and menisci [2]. 
In addition, the other component of the association with 
old age, biological aging, has shown unsuspected 
complexity, including its multidimensionality, variable 
progression, possibility of modulation and the pivotal 
































patients  and  controls.  Therefore,  premature  epigenetic  aging  according  to  DNA  methylation  changes  was
specific of OA cartilage, adding further evidence and insight on premature aging of cartilage as a component of
OA pathogenesis that reflects damage and vulnerability.  
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The many facets of biological aging have been typified 
in nine cellular and molecular hallmarks: genomic 
instability, telomere attrition, epigenetic alterations, loss 
of proteostasis, deregulated nutrient sensing, mito-
chondrial dysfunction, cellular senescence, stem cell 
exhaustion, and altered intercellular communication [6]. 
Variable progression of biological aging with 
dissociation between biological and chronological age is 
observed in progeroid syndromes. Less dramatically, it 
is also observed as a reflection of lifestyle with 
smoking, heavy drinking, obesity, stress and depression 
as accelerators, and exercise and caloric restriction as 
rejuvenators. The pivotal role of cellular senescence and 
of the senescence-associated secretory phenotype has 
been established in multiple studies, but most strikingly 
with the reversal of age-associated changes obtained 
with their removal [7]. This rejuvenation has been 
obtained either through genetic manipulation or with 
senolytic drugs in mice in spite of the eliminated 
senescent cells were only a minor fraction in mouse 
tissues [5]. All these aspects could be of relevance for 
OA as exemplified by the secretory phenotype that 
includes secretion of metalloproteases and pro-
inflammatory mediators, which could be involved in 
OA cartilage damage [2-4]. There is already persuasive 
evidence of accelerated biological aging at the affected 
cartilage [3, 4]. Many of the aging hallmarks have been 
described as exacerbated in OA chondrocytes and 
articular cartilage, including telomere length shortening, 
mitochondrial dysfunction, cellular senescence and 
genome instability [3, 4]. In contrast, biological age has 
not been studied in any other joint tissue although a 
systemic component of premature aging has been 
suggested by accelerated telomere length shortening in 
blood cells of 160 hand OA subjects compared with 926 
controls [8]. Telomere shortening correlated with 
radiographic severity of OA in the hands in this study. 
These findings have not yet been independently 
confirmed, with a small subsequent study showing no 
telomere attrition in blood of knee OA patients [9], and 
a second small study reporting telomere shortening only 
in knee OA patients experiencing high stress and 
chronic pain [10]. A systemic premature aging 
component in OA is an attractive hypothesis because it 
is congruent with some epidemiological studies that 
have found increased prevalence of old-age 
comorbidities [11-14], frailty [15], and mortality in OA 
patients [16-18]. The two aspects, local and systemic, of 
premature aging could contribute to OA by further 
impairing cartilage and joint function, decreasing 
mobility and increasing joint vulnerability.  
 
An opportunity to explore a different aging hallmark in 
OA cartilage, bone and blood has become possible 
thanks to the recent development of biomarkers of 
epigenetic aging [19-24]. The available biomarkers, 
called DNA methylation age-measures (DmAM), 
combine methylation levels at CpG sites that experience 
methylation changes with aging. The mechanism seems 
to include slowly accumulating failures of methylation 
maintenance (epigenetic drift) that could be accelerated 
by somatic mutations, cell divisions and environmental 
stress [19, 21, 25, 26]. Some of the changes are tissue-
specific; others are shared by several tissues. This 
motivates a distinction between DmAM that are tissue-
specific and include as few as 3 CpG sites showing 
strong correlation with age in blood, [20, 24] or in 
saliva [23], and biomarkers  applicable to many tissues 
that require investigating more CpG sites [19, 21]. The 
most comprehensive is the "epigenetic clock" method 
by Horvath, which includes 353 CpG and is valid for 
multiple tissues including bone and cartilage [19, 27, 
28]. The DmAM are useful biomarkers of biological 
age that show accelerated aging in several diseases of 
old age [19-21, 29, 30] and in subjects under elevated 
lifetime stress [26], and that correlate with cognitive 
and physical fitness in the elderly and with all-cause 




The cartilage samples from OA patients showed 
premature aging in comparison with cartilage from 
controls (Figure 1A). The difference in the estimated 
mean age obtained with Horwath’s DmAM was of 3.7 
years (Table 1). This result was obtained with the whole 
set of samples that included cartilage from the tibial 
plateau and from the femoral head. A significant 
premature aging was also observed with the subgroup of 
tibial plateau samples, with a mean difference of 5.3 
years (95 % CI = 2.4 to 8.2). Cartilages from the femoral 
heads were too few for meaningful analysis.  All the 
comparisons were adjusted for age and sex as covariates. 
 
In contrast with the cartilage results, there were no 
differences in epigenetic aging of bone (Figure 1B). The 
mean estimated age obtained from DNA methylation 
data was very similar in patients with hip OA and in 
controls (Table 1). The lack of difference was validated 
in a sub-analysis including only the fracture controls 
(ΔDmAM = 0.5 years, 95 % CI = -1.50 to 2.54, P = 
0.6). Bone samples from cadaver controls were too few 
for meaningful analysis. All the comparisons were 
adjusted for age and sex as covariates. 
 
The study of epigenetic aging in blood required de novo 
analyzes of methylation levels at the 8 CpG sites.  The 
MS-SNuPE assays showed a 93.0 % call rate, and 
between-plate CV of 3.2 %. Age of the 182 controls 
without OA was accurately predicted with the 8CpG 
DmAM (Figure 2), as shown by the good fit of the 
mean age estimate (mean difference age – DmAM = -
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0.1 years, SD = 8.7 years). Comparison of the 
epigenetic ages obtained in this way did not show 
differences between OA patients and controls (Figure 
2). The epigenetic ages for each of the joint-specific OA 
subgroups were very similar to the epigenetic age for 
the control subjects, as shown for the hand OA patients 


















































patients (Figure 2C). This similarity in blood cells was 
clearly shown by the near zero year ΔDmAM (Table 1). 
The largest difference in blood was observed between 
patients with hip OA and controls, but it was not 
significant and with direction opposed to premature 
aging in the OA subjects. All the comparisons were 















































Figure 1. Comparison of epigenetic age  in  joint tissues  from controls and patients with OA.
(A) Accelerated aging in OA cartilage samples (n = 31) in comparison with control cartilage (n =
36) with ΔDmAM = 3.7 years (P = 0.008); and (B) no difference (ΔDmAM = 0.04 years, P = 0.3) in
bone  samples  between  OA  patients  (n  =  33)  and  controls  (n  =  45).  Epigenetic  ages  are
represented as age‐ and sex‐adjusted values with horizontal lines for the mean of each group. 
Table 1. Specific premature epigenetic aging in OA cartilage 
compared with  control  cartilage.  ΔDmAM  =  (age‐  and  sex‐
adjusted  mean  DmAM  in  OA  patients)  –  (age‐  and  sex‐
adjusted mean DmAM in controls); CI = confidence interval. 
 
Tissue OA set ΔDmAMa (95% CI) P-value 
Cartilage Knee/hip 3.7 (1.1 to 6.3) 0.008 
    
Bone Hip 0.04 (-1.8 to 1.9) 0.3 
    
Blood Hand 0.01 (-1.1 to 1.1) 0.98 
Knee 0.04 (-0.9 to 1.0) 0.9 
Hip -0.7 (-1.7 to 0.3) 0.11 
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DISCUSSION 
 
Our results showed for the first time premature 
epigenetic aging as detected with DmAM in cartilage of 
the OA affected joint, but not in bone nearby the OA 
affected joint, or in blood cells of OA patients 
irrespective of the joint affected. These results add 
epigenetic aging to the list of hallmarks of aging 
showing accelerated changes in OA cartilage. Each of 
these hallmarks provide complementary and non-
redundant evidence of the different facets of the 
premature biological aging taking place in chondrocytes 
and the extracellular matrix of the OA affected 
cartilage. In addition, our results could be interpreted as 
questioning systemic premature aging in OA, or even a 
local component of premature aging in nearby bone, but 
exploration of other aging hallmarks would be required 
to exclude them. 
 
Previously, several hallmarks of biological aging have 
been found exacerbated in chondrocytes and cartilage 
from OA patients [3, 4]. Our work adds epigenetic 
aging to the list of hallmarks that show premature 
biological aging in this tissue. This is a significant 
addition because the different aging hallmarks, although 
extensively interconnected, show tissue and disease 
specificity and the involvement of each of them cannot 
be assumed from the presence of other hallmarks [5, 6, 
35]. They need to be tested in the specific tissue or 
situation under study. This necessity is exemplified by 
the lack of correlation between epigenetic age and 
telomere length observed in the elderly population [35]. 
In addition, diseases of abnormal telomere attrition are 
different from diseases in which the dominant 
mechanism is genomic instability and both are different 
from normal aging. The first group includes pulmonary 
fibrosis, dyskeratosis congenita and aplastic anemia, 
whereas genome instability is the dominant aging 
hallmark in progeroid syndromes such as Hutchinson-
Gilford progeria syndrome and Werner’s syndrome [5, 
6]. In addition, the DNA methylation changes that are 
included in the Horvath DmAM have been shown to be 
independent from cellular senescence and mitotic age 
[19]. Similar lack of redundancy is observed between 
the other aging hallmarks, making it necessary to study 
each of them to know their involvement in OA. 
 
Epigenetic changes with age are not restricted to DNA 
methylation. They encompass also histone modifica-
tions regulated by sirtuins and chromatin remodeling 
[6]. None of the other age-associated epigenetic changes 
has yet been analyzed in the context of OA, but they are 
of interest given their potential reversibility as with 
histone deacetylase inhibitors or inhibitors of histone 
acetyltransferases as anti-aging drugs [6]. The meaning 
of these epigenetic changes is still poorly understood. 
They likely contribute to the loss of transcriptional 
regulation and increase of transcriptional noise observed 
with aging [5, 6]. Changes in DNA methylation are 
concentrated in genes with some functional categories 
including cell growth and survival, organismal 
























































the  hip  OA  (n  =  273)  patients  (filled  circles).  Straight  lines
represent least squares regression fit to the data. 
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corticoid response elements [26], but the pattern of 
hypermethylation and hypomethylation has not yet 
being linked to specific molecular or cellular processes 
[19, 20]. Interpretation of the changes should also 
include the magnitude of the change: the increase in 3.7 
years in ΔDmAM observed in the OA cartilage samples 
of our study is a modest acceleration compared with 
changes observed in tumoral tissue, but similar to the 
reported in a recent abstract in hip OA cartilage, which 
provides independent confirmation of our findings [36], 
and in blood of HIV infected patients [37], or in blood 
of Down syndrome patients [29], but larger than the 
observed in blood from patients with Parkinson disease 
[38], or in blood of women after menopause [39]. 
 
Some of the previously described aging hallmarks are 
strongest in the damaged cartilage and less clear in 
cartilage of preserved areas. Hallmarks showing this 
pattern are mean telomere length shortening [40-42] 
senescence-associated heterochromatin foci [41, 42], 
and senescence-associated β-galactosidase (SA-β-gal). 
These results have been interpreted as representing, at 
least in part, consequences of cellular stress and the 
senescence status of the chondrocytes in OA. However, 
it is possible that epigenetic aging is a biomarker of 
cellular vulnerability more than of damage and, 
therefore, a potential target for treatment. Experiments 
aimed to differentiate between the two mechanisms are 
necessary but there are already preliminary results 
showing similar epigenetic aging in damaged and in 
preserved cartilage from the same OA patient [36].  
Potential treatments could include specific senolytic 
drugs [5] that have not yet been assayed in chondro-
cytes, and other approaches with capacity to delay aging 
in OA chondrocytes as already shown for statins [38] 
and sirtuin activation [37, 39]. 
 
Our results are contrary to widespread premature 
epigenetic aging given the lack of increased ΔDmAM at 
the blood and bone levels. However, the only previous 
direct evidence of a systemic component of accelerate 
aging in OA was obtained with telomere length in blood 
cells of OA patients [8, 10], and it is likely that telomere 
length and DmAM capture different aspects of 
biological aging [6, 19, 21, 25, 27]. Telomere attrition 
results from cell divisions, in the absence of the enzyme 
telomerase, and from DNA damage induced by extrinsic 
stress, as oxidative or inflammatory stress. The authors 
that found accelerated telomere length attrition in blood 
of OA patient interpreted it as reflecting oxidative stress 
and low-level chronic inflammation [8], or associated 
with chronic pain and high stress [10]. In contrast, 
epigenetic aging as measured with DmAM seems to be 
due to perturbations of the DNA methylation mainte-
nance system [19, 21, 25]. Therefore, our results do not 
question systemic accelerated aging as detected with 
telomere shortening, but exclude the epigenetic aspect 
of aging. 
 
The lack of accelerated aging in blood and in bone was 
not attributable to insufficient power. In effect, blood 
samples were enough to exclude ΔDmAM half as fast 
as the observed in cartilage (1-β > 0.95 to exclude a 
difference of 1.83 years for each of the three joints). 
Bone samples, in turn, were enough to detect ΔDmAM 
as large as the observed in cartilage (1-β = 0.90). In 
addition, the use of different DmAM for cartilage and 
bone, in one side, and for blood, in the other, does not 
interfere with our results because no analysis compared 
results across different DmAM. We also avoided biases 
due to differences in age or sex between the OA patients 
and the controls by adjusting for these two variables, as 
recommended [19-21]. However, limitations of our 
study are that the different tissues were not from the 
same subjects, the lack of other joint tissues, and the 
absence of a larger number of cartilage samples from 
femoral heads allowing specific analysis of epigenetic 
aging at this site. The meaning of these limitations 
seems modest because bone and cartilage are arguably 
the most relevant tissues in OA [2], and because 
epigenetic aging in hip cartilage from OA patients has 
been independently found [36], as already mentioned. 
In any case, we cannot completely exclude that other 
tissues or joints show a different behavior than the 
reporter here, or that additional insight could be gained 
from analyzing several tissues from the same subjects, 
as epigenetic age correlation between tissues. 
 
In summary, we have found specific accelerated aging 
as measured with DNA methylation in cartilage from 
OA affected joints. Knowledge of the mechanisms of 
this type of premature aging will help to understand OA 
pathology, but already it is apparent that these particular 
mechanisms are not widespread. This was indicated by 
the results obtained with the same DNA methylation 
methodology in bone near the affected joint and in 
blood cells. They showed absence of a systemic 
component of premature aging. These results cannot 
exclude that other hallmarks of aging could be more 





Cartilage and bone epigenetic age 
 
Epigenetic age was estimated with the 353 age-related 
CpG probes according with Horvath [19]. Methylation 
information of these sites has been obtained in previous 
studies addressing cartilage and bone samples (Table 2 
and Supplementary Table 1) [43-46]. Cartilage samples 
were from 31 controls and 36 OA patients (Table 2).  


























The controls were from tibial plateau of 18 cadavers 
with no macroscopic signs of OA [43], and the femoral 
head of 10 subjects with hip fracture and without 
macroscopic or microscopic evidence of OA [46]. In 
addition, 3 cartilage samples from cadavers without 
information of status and location were included [45]. 
The OA samples included 29 from the tibial plateau of 
severe knee OA patients [43, 46], and 7 from the 
femoral head of severe hip OA patients [46], obtained at 
the time of joint replacement. Bone samples were from 
45 controls and 33 hip OA patients (Table 2). The 
controls included femoral heads of 34 subjects with 
osteoporotic hip fracture (OP) and 7 cadavers [44]. 
They lacked OA lesions on macroscopic examination of 
the hip joints and the bone pieces excluded subchondral 
and fractured regions. Patients with fractures due to 
high-energy trauma or with disorders causing secondary 
OP or OA were not included.  In addition, 4 control 
bone samples from cadavers that lacked detailed 
information of status and place of retrieval were 
included.[45] The bone samples of the 33 hip OA 
patients were obtained from femoral heads at the time 
of total joint replacement for primary hip OA [44]. 
Methylation data were obtained either with the Human 
Methylation 27 BeadChip (Illumina), [43, 44] or with 
the HumanMethylation 450 Bead-Chip microarray 
(Illumina, San Diego, California, USA) [45, 46]. These 
samples were obtained with informed consent of the 
donors and approval of the relevant ethics committees 


























Analysis of epigenetic aging in blood 
 
Epigenetic aging in blood was assessed with a 8 CpG 
DmAM specific for whole blood and amenable to assay 
in large number of samples [24]. Methylation data were 
obtained for this study with methylation-sensitive 
single-nucleotide primer extension (MS-SNuPE) 
following the reported procedure [47]. Genomic DNA 
from 890 subjects of Spanish ancestry was assayed 
(Table 2 and Supplementary Table 1). This collection of 
samples included 182 controls recruited at the time of 
intravenous urography. They had not OA signs at 
exploration including both hands or in the radiographs 
either at the hip or column joints, and they did not 
complain of OA symptoms in a systematic question-
naire. The remaining 708 subjects were suffering from 
primary OA as assessed by a rheumatologist. The 
subjects affected by knee OA, 229, or hip OA, 273, 
were selected from consecutive patients aged 55–
75 years at the time of surgery that were undergoing 
total joint replacement. The patients with hand OA, 206, 
were selected among those attending the Rheumatology 
Unit fulfilling the American College of Rheumatology 
classification criteria for hand OA [48]. Exclusion 
criteria were inflammatory, infectious, traumatic or 
congenic joint pathology, as well as, lesions due to 
crystal deposition or osteonecrosis. Morbid obesity and 
occupational strain were not exclusion causes. All 
donors provided blood DNA samples for genetic studies 




Tissue Set N 
Age  
Mean ± SD (Range) Woman % 
Cartilage Control knee/hipa 31 64.8 ± 15.0 (40-95) 48.4 
 Knee/hip OA 36 67.1 ± 9.3 (41-80) 75.0 
     
Bone Control hipa 45 78.0 ± 11.0 (40-104) 93.3 
 Hip OA 33 75.4 ± 6.7 (58-89) 100.0 
     
Blood Control 182 60.7 ± 11.5 (45-88) 46.7 
Hand OA 206 60.6 ± 10.1 (32-88) 88.4 
Knee OA 229 67.7 ± 5.6 (55-78) 82.1 
Hip OA 273 68.4 ± 5.5 (55-84) 59.7 
a 3 cartilage and 4 bone control samples were from undefined localization 
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Declaration of Helsinki (most recently at the General 
Assembly on October 2008) and the approval of the 





We estimated the epigenetic age of the cartilage and 
bone samples with Horvath’s DmAM [19], and of the 
blood samples with the 8 CpG DmAM [24]. 
Comparisons between samples from OA patients and 
controls were done with analysis of variance (ANOVA) 
including age and sex as covariates. Mean differences in 
DmAM estimates (ΔDmAM) were calculated as: 
 
ΔDmAM = (age- and sex-adjusted mean DmAM in OA 
patients) – (age- and sex-adjusted mean DmAM in 
controls) 
 
Age- and sex-adjustment was done with the residuals 
from multiple linear regression of estimated age versus 
age and sex. All these analyses were done with 
Statistica 7.0 (Stat Soft, Inc.). Post-hoc power analysis 
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Tissue Study Set N Age Mean Age Range Std.Dev. Woman %
Blood Current study 
Controls 182 60.70 45 to 88 11.51 46.70 
Hand OA 206 60.58 32 to 88 10.06 88.35 
Knee OA 229 67.66 55 to 78 5.63 82.09 
Hip OA 273 68.38 55 to 84 5.50 59.70 
Cartilage 
Fernández-Tajes J et al, Ann Rheum Dis 2014; 73:668 
Knee Controls 18 59.28 40 to 79 10.83 33.33 
Knee OA 29 68.52 54 to 79 7.25 69.00 
Aref-Eshghi E et al, BMC Musculoskelet Disord 2015; 16:287 
Knee OA 6 65.35 54 to 78 10.63 100.00 
Hip Controls 10 79.37 63 to 95 11.38 90.00 
Hip OA 7 60.93 41 to 80 14.29 100.00 
Lokk K et al, Genome Biol 2014; 15:R54 
Controls 3 49.00 40 to 54 7.81 0.00 
Bone 
Controls 4 51.75 40 to 60 8.42 25.00 
Delgado-Calle J et al, Arthritis Rheum 2013; 65:197 
Hip Cadaver 7 80.29 69 to 92 8.08 100.00 
Hip Fracture 34 80.68 65 to 104 7.11 100.00 
Hip OA 33 75.42 58 to 89 6.74 100.00 
 
